|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
84,190,000 |
Market
Cap: |
10.38(B) |
Last
Volume: |
427,350 |
Avg
Vol: |
426,189 |
52
Week Range: |
$67.31 - $141.53 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 983 |
Guru Rank Value : 0 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Co. is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy, Limb-girdle muscular dystrophies and other neuromuscular and central nervous system related disorders. Co.'s commercial product, EXONDYS 51® (eteplirsen) Injection is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
143,757 |
247,027 |
Total Buy Value |
$0 |
$0 |
$13,295,068 |
$24,257,422 |
Total People Bought |
0 |
0 |
3 |
3 |
Total Buy Transactions |
0 |
0 |
5 |
7 |
Total Shares Sold |
4,396 |
27,731 |
42,731 |
43,589 |
Total Sell Value |
$602,450 |
$3,499,041 |
$5,099,841 |
$5,194,152 |
Total People Sold |
2 |
7 |
7 |
7 |
Total Sell Transactions |
2 |
7 |
8 |
9 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Behrens M Kathleen |
Director |
|
2011-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
110,000 |
|
- |
|
Price Ben Gil |
Director |
|
2011-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
167,982 |
|
- |
|
Wigzell Hans Lennart Rudolf |
Director |
|
2011-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
Goolsbee William Alden |
Director |
|
2011-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
20,000 |
|
- |
|
Chase Anthony R |
Director |
|
2011-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
396,467 |
|
- |
|
Hodgman John |
Director |
|
2011-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
15,000 |
|
- |
|
Christopher Nishan Garabedian |
President and CEO |
|
2011-04-06 |
4 |
B |
$1.50 |
$195,000 |
D/D |
130,000 |
130,000 |
2.81 |
- |
|
Behrens M Kathleen |
Director |
|
2011-04-06 |
4 |
B |
$1.50 |
$150,000 |
D/D |
100,000 |
105,000 |
2.39 |
- |
|
Price Ben Gil |
Director |
|
2011-04-06 |
4 |
B |
$1.50 |
$30,000 |
D/D |
20,000 |
162,982 |
2.39 |
- |
|
Boyle J David Ii |
CEO |
|
2010-08-27 |
4 |
B |
$2.13 |
$10,645 |
D/D |
5,000 |
70,282 |
2.74 |
- |
|
Price Ben Gil |
Director |
|
2010-08-13 |
4 |
B |
$1.93 |
$7,720 |
D/D |
4,000 |
102,982 |
2.39 |
- |
|
Hudson Leslie |
Former CEOFormer CEO |
|
2010-07-30 |
4 |
S |
$1.92 |
$354,113 |
D/D |
(183,486) |
384,559 |
|
- |
|
Hudson Leslie |
Former CEOFormer CEO |
|
2010-07-30 |
4 |
OE |
$1.09 |
$200,000 |
D/D |
183,486 |
568,045 |
|
- |
|
Hudson Leslie |
Former CEOFormer CEO |
|
2010-07-28 |
4 |
S |
$1.81 |
$334,373 |
D/D |
(183,486) |
384,559 |
|
- |
|
Hudson Leslie |
Former CEOFormer CEO |
|
2010-07-28 |
4 |
OE |
$1.09 |
$200,000 |
D/D |
183,486 |
568,045 |
|
- |
|
Hudson Leslie |
Former CEOFormer CEO |
|
2010-07-26 |
4 |
S |
$1.89 |
$245,897 |
D/D |
(129,083) |
384,559 |
|
- |
|
Hudson Leslie |
Former CEOFormer CEO |
|
2010-07-26 |
4 |
OE |
$1.45 |
$187,170 |
D/D |
129,083 |
513,642 |
|
- |
|
Hudson Leslie |
Former CEOFormer CEO |
|
2010-07-23 |
4 |
S |
$1.80 |
$369,720 |
D/D |
(205,400) |
384,559 |
|
- |
|
Hudson Leslie |
Former CEOFormer CEO |
|
2010-07-23 |
4 |
OE |
$1.45 |
$297,830 |
D/D |
205,400 |
589,959 |
|
- |
|
Hudson Leslie |
Former CEOFormer CEO |
|
2010-07-22 |
4 |
S |
$1.79 |
$477,513 |
D/D |
(265,517) |
384,559 |
|
- |
|
Hudson Leslie |
Former CEOFormer CEO |
|
2010-07-22 |
4 |
OE |
$1.45 |
$385,000 |
D/D |
265,517 |
650,076 |
|
- |
|
Hudson Leslie |
Former CEOFormer CEO |
|
2010-07-16 |
4 |
S |
$1.85 |
$188,114 |
D/D |
(100,028) |
384,559 |
|
- |
|
Hudson Leslie |
Former CEOFormer CEO |
|
2010-07-16 |
4 |
OE |
$1.09 |
$109,031 |
D/D |
100,028 |
484,587 |
|
- |
|
Hudson Leslie |
Former CEOFormer CEO |
|
2010-07-09 |
4 |
S |
$1.55 |
$316,127 |
D/D |
(200,000) |
384,559 |
|
- |
|
Hudson Leslie |
Former CEOFormer CEO |
|
2010-07-09 |
4 |
OE |
$1.09 |
$218,000 |
D/D |
200,000 |
434,559 |
|
- |
|
524 Records found
|
|
Page 17 of 21 |
|
|